United States - English - NLM (National Library of Medicine)

rebel distributors corp - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide   inhalation solution 0.02%   read complete instructions carefully before using. - twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir. (figure 1). - connect the nebulizer reservoir to the mouth piece or face mask (figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) or put on the face mask and turn on the compressor. if a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of

United States - English - NLM (National Library of Medicine)

rebel distributors corp - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk) - tobramycin ophthalmic solution is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution. clinical studies have shown tobramycin to be safe and effective for use in children. tobramycin ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular antibacterial drug in this product is active agains

United States - English - NLM (National Library of Medicine)

rebel distributors corp - flurazepam hydrochloride (unii: 756rdm536m) (flurazepam - unii:ihp475989u) - flurazepam hydrochloride 30 mg - flurazepam hydrochloride capsules are a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. flurazepam hydrochloride capsules can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. sleep laboratory studies have objectively determined that flurazepam hydrochloride capsules are effective for at least 28 consecutive nights of drug administration. since insomnia is often transient and intermittent short-term use is usually sufficient. prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. flurazepam hydrochloride capsules are contraindicated in patients with known hypersensitivity to the drug. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated wi

United States - English - NLM (National Library of Medicine)

rebel distributors corp - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - hydralazine hydrochloride 10 mg - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - triamcinolone acetonide (unii: f446c597ka) (triamcinolone - unii:1zk20vi6ty) - triamcinolone acetonide 0.25 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - diphenoxylate hydrochloride and atropine sulfate tablets are effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in patients with - known hypersensitivity to diphenoxylate or atropine, - obstructive jaundice, - diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochlor

United States - English - NLM (National Library of Medicine)

rebel distributors corp - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - ciprofloxacin 3 mg in 1 ml - ciprodex® otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: acute otitis media in pediatric patients (age 6 months and older) with tympanostomy tubes due to staphylococcus aureus , streptococcus pneumoniae , haemophilus influenzae , moraxella catarrhalis , and pseudomonas aeruginosa . acute otitis externa in pediatric (age 6 months and older), adult and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa . ciprodex® otic is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication. use of this product is contraindicated in viral infections of the external canal including herpes simplex infections. the safety and efficacy of ciprodex® otic have been established in pediatric patients 6 months and older (937 patients) in adequate and well-controlled clinical trials. although no data are available

United States - English - NLM (National Library of Medicine)

rebel distributors corp - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 250 mg - cellcept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. cellcept should be used concomitantly with cyclosporine and corticosteroids. cellcept intravenous is an alternative dosage form to cellcept capsules, tablets and oral suspension. cellcept intravenous should be administered within 24 hours following transplantation. cellcept intravenous can be administered for up to 14 days; patients should be switched to oral cellcept as soon as they can tolerate oral medication. allergic reactions to cellcept have been observed; therefore, cellcept is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. cellcept intravenous is contraindicated in patients who are allergic to polysorbate 80 (tween).

United States - English - NLM (National Library of Medicine)

rebel distributors corp - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital 50 mg - butalbital, aspirin and caffeine tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. hypersensitivity to aspirin, caffeine or barbiturates. patients with porphyria. butalbital, aspirin, and caffeine tablets are classified as a schedule iii controlled substance. prolonged use of barbiturates can produce drug dependence, characterized by psychic dependence, and less frequently, physical dependence and tolerance. the abuse liability of butalbital, aspirin, and caffeine tablets are similar to that of other barbiturate-containing drug combinations. caution should be exercised when prescribing medication for patients with a known propensity for taking excessive quantities of drugs, which is not uncommon in patients with chronic tension headache.